Injeção subaracnoidea da associação ifenprodil e cetamina melhora a ação anti-hiperalgésica da cetamina em cães

To test clinically whether a small dose of ifenprodil can enhance the anti-hyperalgesic effect of ketamine in dogs, a prospective randomized cross-over study was done with eight mongrel dogs (weighing 16.9 ± 3.7kg). Animals received two distinct treatments: ketamine (0.3mg kg-1; KT) and an ifenprodil plus ketamine combination (0.03mg kg-1 and 0.3mg kg-1, respectively; IKT). Dogs were anesthetized with propofol (5mg kg-1 intravenously) and a subarachnoid needle was placed between the 5th and 6th lumbar vertebrae. Five minutes after subarachnoid injection of KT or IKT, an incision including cutaneous and subcutaneous tissues was made on the common pad of one hind limb and was immediately closed with a simple interrupted suture pattern. The dogs were treated again 20 days later, using the contralateral pad and the opposite treatment. Sedation score (SS), lameness score (LS), heart rate (HR), respiratory rate (fR), and mechanical nociceptive threshold using von Frey filaments, were evaluated before anesthesia and at 1, 1.5, 2, 3, 4, 8, 12, and 24 hours after subarachnoid injection. There were no differences in SS, LS, HR or fR between treatments. The intensity of hyperalgesia was higher in KT than in IKT for 24 hours. The anti-hyperalgesic effect of IKT remained without statistical significant difference between 1 and 24 h. Prior subarachnoid administration of ifenprodil enhances the anti-hyperalgesic effect of subarachnoid ketamine in dogs. Ifenprodil can be co-administrated with ketamine to enhance its anti-hyperalgesic effect and to reduce acute post-incisional hyperalgesia without motor impairment and sedation.67615391546COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPESFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPSem informaçãoSem informaçãoCom a finalidade de testar se uma dose baixa de ifenprodil pode melhorar a ação anti-hiperalgésica da cetamina em cães, um estudo randomizado prospectivo no formato cross-over foi realizado em oito cães sem raça definida (pesando 16,9±3.7kg). Os animais receberam dois tratamentos distintos: cetamina (0,3mg kg-1; KT) e a associação de ifenprodil com cetamina (0,03mg kg-1 e 0,3mg kg-1, respectivamente; IKT). Os cães foram anestesiados com propofol (5mg kg-1, via intravenosa), e uma agulha subaracnoidea foi introduzida entre a quinta e sexta vértebras lombares. Após cinco minutos da injeção subaracnoidea de KT ou IKT, uma incisão abrangendo os tecidos cutâneo e subcutâneo foi realizada no coxim plantar comum de um dos membros pélvicos e imediatamente fechada com um padrão de sutura simples e interrompido. Os cães foram novamente tratados após 20 dias, usando-se o coxim plantar contralateral e o outro tratamento. Os escores de sedação (SS) e claudicação (LS); as frequências cardíacas (HR) e respiratória (fR) e o limiar nociceptivo ao estímulo mecânico, utilizando os filamentos de von Frey, foram avaliados antes da anestesia e uma, uma e meia; duas; três; quatro; oito; 12 e 24 horas após a injeção subaracnoidea. Não foram observadas diferenças significativas em SS, LS, HR ou na fR entre os tratamentos. A intensidade da hiperalgesia foi maior em KT que em IKT nas 24 horas. O efeito anti-hiperalgésico de IKT se manteve sem diferença significativa entre os tempos uma hora e 24 horas. A administração prévia de ifenprodil aumentou a ação anti-hiperalgésica da cetamina subaracnoidea em cães. O ifenprodil pode ser coadministrado com cetamina para aumentar seu efeito anti-hiperalgésico e reduzir a hiperlagesia aguda pós-incisional, sem alterações motoras e sedação

Streptozotocin-induced mechanical hypernociception is not dependent on hyperglycemia

Since streptozotocin (STZ)-induced diabetes is a widely used model of painful diabetic neuropathy, the aim of the present study was to design a rational protocol to investigate whether the development of mechanical hypernociception induced by STZ depends exclusively on hyperglycemia. Male Wistar rats (180-200 g; N = 6-7 per group) received a single intravenous injection of STZ at three different doses (10, 20, or 40 mg/kg). Only the higher dose (40 mg/kg) induced a significant increase in blood glucose levels, glucose tolerance and deficiency in weight gain. However, all STZ-treated rats (hyperglycemic or not) developed persistent (for at least 20 days) and indistinguishable bilateral mechanical hypernociception that was not prevented by daily insulin treatment (2 IU twice a day, sc). Systemic morphine (2 mg/kg) but not local (intraplantar) morphine treatment (8 µg/paw) significantly inhibited the mechanical hypernociception induced by STZ (10 or 40 mg/kg). In addition, intraplantar injection of STZ at doses that did not cause hyperglycemia (30, 100 or 300 µg/paw) induced ipsilateral mechanical hypernociception for at least 8 h that was inhibited by local and systemic morphine treatment (8 µg/paw or 2 mg/kg, respectively), but not by dexamethasone (1 mg/kg, sc). The results of this study demonstrate that systemic administration of STZ induces mechanical hypernociception that does not depend on hyperglycemia and intraplantar STZ induces mechanical sensitization of primary sensory neurons responsive to local morphine treatment.FAPESPCNPqPrograma de Núcleos de Excelência (PRONEX

Peripheral Sensitization Increases Opioid Receptor Expression And Activation By Crotalphine In Rats

Inflammation enhances the peripheral analgesic efficacy of opioid drugs, but the mechanisms involved in this phenomenon have not been fully elucidated. Crotalphine (CRP), a peptide that was first isolated from South American rattlesnake C.d. terrificus venom, induces a potent and long-lasting anti-nociceptive effect that is mediated by the activation of peripheral opioid receptors. Because the high efficacy of CRP is only observed in the presence of inflammation, we aimed to elucidate the mechanisms involved in the CRP anti-nociceptive effect induced by inflammation. Using real-time RT-PCR, western blot analysis and ELISA assays, we demonstrate that the intraplantar injection of prostaglandin E2 (PGE2) increases the mRNA and protein levels of the μ- and κ-opioid receptors in the dorsal root ganglia (DRG) and paw tissue of rats within 3 h of the injection. Using conformation state-sensitive antibodies that recognize activated opioid receptors, we show that PGE 2, alone does not increase the activation of these opioid receptors but that in the presence of PGE2, the activation of specific opioid receptors by CRP and selective μ- and κ-opioid receptor agonists (positive controls) increases. Furthermore, PGE2 down-regulated the expression and activation of the δ-opioid receptor. CRP increased the level of activated mitogen-activated protein kinases in cultured DRG neurons, and this increase was dependent on the activation of protein kinase Cζ. This CRP effect was much more prominent when the cells were pretreated with PGE 2. These results indicate that the expression and activation of peripheral opioid receptors by opioid-like drugs can be up- or down-regulated in the presence of an acute injury and that acute tissue injury enhances the efficacy of peripheral opioids. © 2014 Zambelli et al.93Stein, C., Peripheral mechanisms of opioid analgesia (1993) Anesth Analg, 76, pp. 182-191Obara, I., Parkitna, J.R., Korostynski, M., Makuch, W., Kaminska, D., Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain (2009) Pain, 141, pp. 283-291Puehler, W., Zollner, C., Brack, A., Shaqura, M.A., Krause, H., Schafer, M., Stein, C., Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction (2004) Neuroscience, 129 (2), pp. 473-479. , DOI 10.1016/j.neuroscience.2004.06.086, PII S030645220400627XMaekawa, K., Minami, M., Masuda, T., Satoh, M., Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats (1996) Pain, 64 (2), pp. 365-371. , DOI 10.1016/0304-3959(95)00132-8Cahill, C.M., Morinville, A., Hoffert, C., O'Donnell, D., Beaudet, A., Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: Implications for pain control (2003) Pain, 101 (1-2), pp. 199-208. , DOI 10.1016/S0304-3959(02)00333-0Hassan, A.H.S., Ableitner, A., Stein, C., Herz, A., Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue (1993) Neuroscience, 55 (1), pp. 185-195. , DOI 10.1016/0306-4522(93)90465-RZollner, C., Shaqura, M.A., Bopaiah, C.P., Mousa, S., Stein, C., Schafer, M., Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons (2003) Molecular Pharmacology, 64 (2), pp. 202-210. , DOI 10.1124/mol.64.2.202Shaqura, M.A., Zollner, C., Mousa, S.A., Stein, C., Schafer, M., Characterization of mu Opioid Receptor Binding and G Protein Coupling in Rat Hypothalamus, Spinal Cord, and Primary Afferent Neurons during Inflammatory Pain (2004) Journal of Pharmacology and Experimental Therapeutics, 308 (2), pp. 712-718. , DOI 10.1124/jpet.103.057257Antonijevic, I., Mousa, S.A., Schafer, M., Stein, C., Perineurial defect and peripheral opioid analgesia in inflammation (1995) J Neurosci, 15, pp. 165-172Mousa, S.A., Zhang, Q., Sitte, N., Ji, R.-R., Stein, C., beta-endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue (2001) Journal of Neuroimmunology, 115 (1-2), pp. 71-78. , DOI 10.1016/S0165-5728(01)00271-5, PII S0165572801002715Konno, K., Picolo, G., Gutierrez, V.P., Brigatte, P., Zambelli, V.O., Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus (2008) PeptidesGutierrez, V.P., Zambelli, V.O., Picolo, G., Chacur, M., Sampaio, S.C., The peripheral L-arginine-nitric oxide-cyclic GMP pathway and ATP-sensitive K channels are involved in the antinociceptive effect of crotalphine on neuropathic pain in rats Behav Pharmacol, 23, pp. 14-24Gutierrez, V.P., Konno, K., Chacur, M., Sampaio, S.C., Picolo, G., Crotalphine induces potent antinociception in neuropathic pain by acting at peripheral opioid receptors (2008) Eur J Pharmacol, 594, pp. 84-92Granados-Soto, V., Rufino, M.D.O., Gomes, L.L.D., Ferreira, S.H., Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin tests (1997) European Journal of Pharmacology, 340 (2-3), pp. 177-180. , DOI 10.1016/S0014-2999(97)01399-X, PII S001429999701399XSachs, D., Cunha, F.Q., Ferreira, S.H., Peripheral analgesic blockade of hypernociception: Activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (10), pp. 3680-3685. , DOI 10.1073/pnas.0308382101Pacheco, D.F., Reis, G.M.L., Francischi, J.N., Castro, M.S.A., Perez, A.C., Duarte, I.D.G., delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta1 and delta2 receptors and activation of the L-arginine/nitric oxide/cyclic GMP pathway (2005) Life Sciences, 78 (1), pp. 54-60. , DOI 10.1016/j.lfs.2005.04.032, PII S0024320505006697Amarante, L.H., Duarte, I.D.G., The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway (2002) European Journal of Pharmacology, 454 (1), pp. 19-23. , DOI 10.1016/S0014-2999(02)02275-6, PII S0014299902022756Cunha, T.M., Roman-Campos, D., Lotufo, C.M., Duarte, H.L., Souza, G.R., Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway Proc Natl Acad Sci U S A, 107, pp. 4442-4447Law, B.K., Waltner-Law, M.E., Entingh, A.J., Chytil, A., Aakre, M.E., Norgaard, P., Moses, H.L., Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-Myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen (2000) Journal of Biological Chemistry, 275 (49), pp. 38261-38267. , DOI 10.1074/jbc.M005545200Belcheva, M.M., Clark, A.L., Haas, P.D., Serna, J.S., Hahn, J.W., Kiss, A., Coscia, C.J., Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes (2005) Journal of Biological Chemistry, 280 (30), pp. 27662-27669. , DOI 10.1074/jbc.M502593200Connor, M., Christie, M.J., Opioid receptor signalling mechanisms (1999) Clinical and Experimental Pharmacology and Physiology, 26 (7), pp. 493-499. , DOI 10.1046/j.1440-1681.1999.03049.xZimmermann, M., Ethical guidelines for investigations of experimental pain in conscious animals (1983) Pain, 16, pp. 109-110Picolo, G., Giorgi, R., Bernardi, M.M., Cury, Y., The antinociceptive effect of Crotalus durissus terrificus snake venom is mainly due to a supraspinally integrated response (1998) Toxicon, 36 (1), pp. 223-227. , DOI 10.1016/S0041-0101(97)00048-2, PII S0041010197000482Von Banchet, G.S., Scholze, A., Schaible, H.-G., Prostaglandin E2 increases the expression of the neurokinin1 receptor in adult sensory neurones in culture: A novel role of prostaglandins (2003) British Journal of Pharmacology, 139 (3), pp. 672-680Picolo, G., Giorgi, R., Cury, Y., delta-Opioid receptors and nitric oxide mediate the analgesic effect of Crotalus durissus terrificus snake venom (2000) European Journal of Pharmacology, 391 (1-2), pp. 55-62. , DOI 10.1016/S0014-2999(99)00934-6, PII S0014299999009346Gendron, L., Pintar, J.E., Chavkin, C., Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia (2007) Neuroscience, 150 (4), pp. 807-817. , DOI 10.1016/j.neuroscience.2007.09.060, PII S0306452207012365Lomas, L.M., Barrett, A.C., Terner, J.M., Lysle, D.T., Picker, M.J., Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats (2007) Psychopharmacology, 191 (2), pp. 273-285. , DOI 10.1007/s00213-006-0663-1Ji, Y., Murphy, A.Z., Traub, R.J., Estrogen modulation of morphine analgesia of visceral pain in female rats is supraspinally and peripherally mediated (2007) J Pain, 8, pp. 494-502. , JPicolo, G., Cury, Y., Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta- and kappa-opioid receptor agonist (2004) Life Sciences, 75 (5), pp. 559-573. , DOI 10.1016/S0024-3205(04)00292-9, PII S0024320504002929Randall, L.O., Selitto, J.J., A method for measurement of analgesia activity on inflamed tissue (1957) Arch Inst Pharmacodyn, 111, pp. 209-219Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal Biochem, 72, pp. 248-254Gupta, A., Decaillot, F.M., Gomes, I., Tkalych, O., Heimann, A.S., Conformation state sensitive antibodies to G-protein coupled receptors (2006) J Biol ChemCunha, T.M., Souza, G.R., Domingues, A.C., Carreira, E.U., Lotufo, C.M., Stimulation of peripheral Kappa opioid receptors inhibits inflammatory hyperalgesia via activation of the PI3Kgamma/AKT/nNOS/NO signaling pathway Mol Pain, 8, p. 10Bruchas, M.R., Chavkin, C., Kinase cascades and ligand-directed signaling at the kappa opioid receptor Psychopharmacology, 210, pp. 137-147. , BerlBerra, E., Diaz-Meco, M.T., Dominguez, I., Municio, M.M., Sanz, L., Lozano, J., Chapkin, R.S., Moscat, J., Protein kinase C zeta isoform is critical for mitogenic signal transduction (1993) Cell, 74 (3), pp. 555-563Kwong, K., Lee, L.-Y., Prostaglandin E2 potentiates a TTX-resistant sodium current in rat capsaicin-sensitive vagal pulmonary sensory neurones (2005) Journal of Physiology, 564 (2), pp. 437-450. , DOI 10.1113/jphysiol.2004.078725Southall, M.D., Vasko, M.R., Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons (2001) J Biol Chem, 276, pp. 16083-16091Ferreira, S.H., Lorenzetti, B.B., Prostaglandin hyperalgesia, IV: A metabolic process (1981) Prostaglandins, 21, pp. 789-792Stein, C., Millan, M.J., Shippenberg, T.S., Peter, K., Herz, A., Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors (1989) Journal of Pharmacology and Experimental Therapeutics, 248 (3), pp. 1269-1275Mousa, S.A., Machelska, H., Schafer, M., Stein, C., Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain (2002) Journal of Neuroimmunology, 126 (1-2), pp. 5-15. , DOI 10.1016/S0165-5728(02)00049-8, PII S0165572802000498Furst, S., Riba, P., Friedmann, T., Timar, J., Al-Khrasani, M., Obara, I., Makuch, W., Schmidhammer, H., Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat (2005) Journal of Pharmacology and Experimental Therapeutics, 312 (2), pp. 609-618. , DOI 10.1124/jpet.104.075176Nunez, S., Lee, J.-S., Zhang, Y., Bai, G., Ro, J.Y., Role of peripheral mu-opioid receptors in inflammatory orofacial muscle pain (2007) Neuroscience, 146 (3), pp. 1346-1354. , DOI 10.1016/j.neuroscience.2007.02.024, PII S030645220700173XSchafer, M., Imai, Y., Uhl, G.R., Stein, C., Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia (1995) Eur J Pharmacol, 279, pp. 165-169Zhou, L., Zhang, Q., Stein, C., Schafer, M., Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia (1998) Journal of Pharmacology and Experimental Therapeutics, 286 (2), pp. 1000-1006Lecat, S., Bucher, B., Mely, Y., Galzi, J.-L., Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses (2002) Journal of Biological Chemistry, 277 (44), pp. 42034-42048. , DOI 10.1074/jbc.M203606200Decaillot, F.M., Befort, K., Filliol, D., Yue, S.Y., Walker, P., Kieffer, B.L., Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation (2003) Nature Structural Biology, 10 (8), pp. 629-636. , DOI 10.1038/nsb950Selley, D.E., Breivogel, C.S., Childers, S.R., Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: Increase in opioid agonist efficacy by decreased inactivation of G proteins (1993) Molecular Pharmacology, 44 (4), pp. 731-741Belcheva, M.M., Vogel, Z., Ignatova, E., Avidor-Reiss, T., Zippel, R., Levy, R., Young, E.C., Coscia, C.J., Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves G(betagamma) subunits (1998) Journal of Neurochemistry, 70 (2), pp. 635-645Bohn, L.M., Belcheva, M.M., Coscia, C.J., Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: Evidence for the involvement of protein kinase C and the mitogen- activated protein kinase signaling cascade (2000) Journal of Neurochemistry, 74 (2), pp. 564-573. , DOI 10.1046/j.1471-4159.2000.740564.xBruchas, M.R., Macey, T.A., Lowe, J.D., Chavkin, C., Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes (2006) Journal of Biological Chemistry, 281 (26), pp. 18081-18089. , http://www.jbc.org/cgi/reprint/281/26/18081, DOI 10.1074/jbc.M513640200Sweatt, J.D., Mitogen-activated protein kinases in synaptic plasticity and memory (2004) Curr Opin Neurobiol, 14, pp. 311-317Thomas, G.M., Huganir, R.L., MAPK cascade signalling and synaptic plasticity (2004) Nature Reviews Neuroscience, 5 (3), pp. 173-183Carlezon Jr., W.A., Duman, R.S., Nestler, E.J., The many faces of CREB (2005) Trends in Neurosciences, 28 (8), pp. 436-445. , DOI 10.1016/j.tins.2005.06.005, PII S016622360500158XBruchas, M.R., Xu, M., Chavkin, C., Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2 (2008) Neuroreport, 19, pp. 1417-1422Kreibich, A.S., Blendy, J.A., cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement (2004) Journal of Neuroscience, 24 (30), pp. 6686-6692. , DOI 10.1523/JNEUROSCI.1706-04.2004Bruchas, M.R., Yang, T., Schreiber, S., DeFino, M., Kwan, S.C., Li, S., Chavkin, C., Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase (2007) Journal of Biological Chemistry, 282 (41), pp. 29803-29811. , http://www.jbc.org/cgi/reprint/282/41/29803, DOI 10.1074/jbc.M705540200Melief, E.J., Miyatake, M., Bruchas, M.R., Chavkin, C., Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling (2010) Proc Natl Acad Sci U S A, 107, pp. 11608-11613Velazquez, K.T., Mohammad, H., Sweitzer, S.M., Protein kinase C in pain: Involvement of multiple isoforms (2007) Pharmacological Research, 55 (6), pp. 578-589. , DOI 10.1016/j.phrs.2007.04.006, PII S104366180700084

The impact of patient travel time on disparities in treatment for early stage lung cancer in California

Background Travel time to treatment facilities may impede the receipt of guideline-concordant treatment (GCT) among patients diagnosed with early-stage non-small cell lung cancer (ES-NSCLC). We investigated the relative contribution of travel time in the receipt of GCT among ES-NSCLC patients. Methods We included 22,821 ES-NSCLC patients diagnosed in California from 2006–2015. GCT was defined using the 2016 National Comprehensive Cancer Network guidelines, and delayed treatment was defined as treatment initiation >6 versus ≤6 weeks after diagnosis. Mean-centered driving and public transit times were calculated from patients’ residential block group centroid to the treatment facilities. We used logistic regression to estimate risk ratios and 95% confidence intervals (CIs) for the associations between patients’ travel time and receipt of GCT and timely treatment, overall and by race/ethnicity and neighborhood socioeconomic status (nSES). Results Overall, a 15-minute increase in travel time was associated with a decreased risk of undertreatment and delayed treatment. Compared to Whites, among Blacks, a 15-minute increase in driving time was associated with a 24% (95%CI = 8%-42%) increased risk of undertreatment, and among Filipinos, a 15-minute increase in public transit time was associated with a 27% (95%CI = 13%-42%) increased risk of delayed treatment. Compared to the highest nSES, among the lowest nSES, 15-minute increases in driving and public transit times were associated with 33% (95%CI = 16%-52%) and 27% (95%CI = 16%-39%) increases in the risk of undertreatment and delayed treatment, respectively. Conclusion The benefit of GCT observed with increased travel times may be a ‘Travel Time Paradox,’ and may vary across racial/ethnic and socioeconomic groups

Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotection

Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy. It has been attributed important non-hematopoietic effects to rhEPO, which might underlie cardio and renoprotection. This work aimed to evaluate the effect of rhEPO in a rat model of moderate CRF, focusing on inflammation, oxidative stress and function/renoprotection. Methods: Four groups (n=7) of male Wistar rats were evaluated during a 15 week follow-up period: control (without treatment); rhEPO (50 IU/Kg/wk Recormon®); CRF and CRF+rhEPO. Blood samples were collected at the beginning and 3, 9 and 12 weeks after 3/4 nephrectomy, in order to evaluate: renal function, haematological parameters, iron metabolism and serum proliferative (TGF-B1), inflammatory (TNF-a, CRP, IL-2 and IL-1B) and redox status (MDA, TAS and 3-NT) markers. Kidney gene expression of Il2, Vegf, Nos2 and Nos3 were assessed by real-time PCR. Blood pressure, heart rate and tissues trophy indexes were also estimated. Results: Our data are consistent with a sustained moderate degree of CRF with development of moderate and corrected anaemia and hypertension. The remnant kidney showed a proliferative profile, with increased mass (hypertrophism), upregulated tissue Vegf gene expression, accompanied by increased levels of serum TGF-B1. Serum 3-NT was augmented, suggesting oxidative stress, which was accompanied by a trend to higher kidney Nos gene expression of both isoforms. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also demonstrating a proliferative and antioxidant action, suggesting renoprotection. Conclusion: This study suggests that rhEPO therapy might be recommended in moderate CRF stages in order to efficiently correct not only the anaemia but also the underlying deleterious mechanisms, due to a proliferative and antioxidant action on the remnant kidney.info:eu-repo/semantics/publishedVersio

Methods to estimate aboveground wood productivity from long-term forest inventory plots

Forest inventory plots are widely used to estimate biomass carbon storage and its change over time. While there has been much debate and exploration of the analytical methods for calculating biomass, the methods used to determine rates of wood production have not been evaluated to the same degree. This affects assessment of ecosystem fluxes and may have wider implications if inventory data are used to parameterise biospheric models, or scaled to large areas in assessments of carbon sequestration. Here we use a dataset of 35 long-term Amazonian forest inventory plots to test different methods of calculating wood production rates. These address potential biases associated with three issues that routinely impact the interpretation of tree measurement data: (1) changes in the point of measurement (POM) of stem diameter as trees grow over time; (2) unequal length of time between censuses; and (3) the treatment of trees that pass the minimum diameter threshold (“recruits”). We derive corrections that control for changing POM height, that account for the unobserved growth of trees that die within census intervals, and that explore different assumptions regarding the growth of recruits during the previous census interval. For our dataset we find that annual aboveground coarse wood production (AGWP; in Mg ha−1 year−1 of dry matter) is underestimated on average by 9.2% if corrections are not made to control for changes in POM height. Failure to control for the length of sampling intervals results in a mean underestimation of 2.7% in annual AGWP in our plots for a mean interval length of 3.6 years. Different methods for treating recruits result in mean differences of up to 8.1% in AGWP. In general, the greater the length of time a plot is sampled for and the greater the time elapsed between censuses, the greater the tendency to underestimate wood production. We recommend that POM changes, census interval length, and the contribution of recruits should all be accounted for when estimating productivity rates, and suggest methods for doing this.European UnionUK Natural Environment Research CouncilGordon and Betty Moore FoundationCASE sponsorship from UNEP-WCMCRoyal Society University Research FellowshipERC Advanced Grant “Tropical Forests in the Changing Earth System”Royal Society Wolfson Research Merit Awar

A reduction in the UHE neutrino flux due to neutrino spin precession

Motivated by the stringent flux limits for UHE neutrinos coming from gamma ray burst or active galactic nuclei, we explore the possibility that the active neutrinos generated in such astrophysical objects could oscillate to sterile right handed states due to a neutrino magnetic moment mu_nu. We find that a value as small as mu_nu ~1E-15 mu_B could produce such a transition thanks to the intense magnetic fields that are expected in these objects.Comment: 5 pages, 1 figure, to appear in Physics Letters

Tree height integrated into pantropical forest biomass estimates

Copyright © 2012 European Geosciences Union. This is the published version available at http://www.biogeosciences.net/9/3381/2012/bg-9-3381-2012.htmlAboveground tropical tree biomass and carbon storage estimates commonly ignore tree height (H). We estimate the effect of incorporating H on tropics-wide forest biomass estimates in 327 plots across four continents using 42 656 H and diameter measurements and harvested trees from 20 sites to answer the following questions: 1. What is the best H-model form and geographic unit to include in biomass models to minimise site-level uncertainty in estimates of destructive biomass? 2. To what extent does including H estimates derived in (1) reduce uncertainty in biomass estimates across all 327 plots? 3. What effect does accounting for H have on plot- and continental-scale forest biomass estimates? The mean relative error in biomass estimates of destructively harvested trees when including H (mean 0.06), was half that when excluding H (mean 0.13). Power- and Weibull-H models provided the greatest reduction in uncertainty, with regional Weibull-H models preferred because they reduce uncertainty in smaller-diameter classes (≤40 cm D) that store about one-third of biomass per hectare in most forests. Propagating the relationships from destructively harvested tree biomass to each of the 327 plots from across the tropics shows that including H reduces errors from 41.8 Mg ha−1 (range 6.6 to 112.4) to 8.0 Mg ha−1 (−2.5 to 23.0). For all plots, aboveground live biomass was −52.2 Mg ha−1 (−82.0 to −20.3 bootstrapped 95% CI), or 13%, lower when including H estimates, with the greatest relative reductions in estimated biomass in forests of the Brazilian Shield, east Africa, and Australia, and relatively little change in the Guiana Shield, central Africa and southeast Asia. Appreciably different stand structure was observed among regions across the tropical continents, with some storing significantly more biomass in small diameter stems, which affects selection of the best height models to reduce uncertainty and biomass reductions due to H. After accounting for variation in H, total biomass per hectare is greatest in Australia, the Guiana Shield, Asia, central and east Africa, and lowest in east-central Amazonia, W. Africa, W. Amazonia, and the Brazilian Shield (descending order). Thus, if tropical forests span 1668 million km2 and store 285 Pg C (estimate including H), then applying our regional relationships implies that carbon storage is overestimated by 35 Pg C (31–39 bootstrapped 95% CI) if H is ignored, assuming that the sampled plots are an unbiased statistical representation of all tropical forest in terms of biomass and height factors. Our results show that tree H is an important allometric factor that needs to be included in future forest biomass estimates to reduce error in estimates of tropical carbon stocks and emissions due to deforestation

Carbon uptake by mature Amazon forests has mitigated Amazon nations' carbon emissions

Background: Several independent lines of evidence suggest that Amazon forests have provided a significant carbon sink service, and also that the Amazon carbon sink in intact, mature forests may now be threatened as a result of different processes. There has however been no work done to quantify non-land-use-change forest carbon fluxes on a national basis within Amazonia, or to place these national fluxes and their possible changes in the context of the major anthropogenic carbon fluxes in the region. Here we present a first attempt to interpret results from groundbased monitoring of mature forest carbon fluxes in a biogeographically, politically, and temporally differentiated way. Specifically, using results from a large long-term network of forest plots, we estimate the Amazon biomass carbon balance over the last three decades for the different regions and nine nations of Amazonia, and evaluate the magnitude and trajectory of these differentiated balances in relation to major national anthropogenic carbon emissions. Results: The sink of carbon into mature forests has been remarkably geographically ubiquitous across Amazonia, being substantial and persistent in each of the five biogeographic regions within Amazonia. Between 1980 and 2010, it has more than mitigated the fossil fuel emissions of every single national economy, except that of Venezuela. For most nations (Bolivia, Colombia, Ecuador, French Guiana, Guyana, Peru, Suriname) the sink has probably additionally mitigated all anthropogenic carbon emissions due to Amazon deforestation and other land use change. While the sink has weakened in some regions since 2000, our analysis suggests that Amazon nations which are able to conserve large areas of natural and semi-natural landscape still contribute globally-significant carbon sequestration. Conclusions: Mature forests across all of Amazonia have contributed significantly to mitigating climate change for decades. Yet Amazon nations have not directly benefited from providing this global scale ecosystem service. We suggest that better monitoring and reporting of the carbon fluxes within mature forests, and understanding the drivers of changes in their balance, must become national, as well as international, priorities